Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.

"Potential conflicts of interest. S. K. G. has received research grants from Merck & Co., Inc., Janssen Pharmaceutics, Inc., and Gilead Sciences, Inc.; travel support from Gilead Sciences, Inc.; and advisory/consultancy/lecture fees from Bristol-Myers Squibb and Merck & Co., Inc. C. T. has received payment for participation on a data monitoring committee for Janssen Therapeutics. E. S. D. has received research grants from Bristol-Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., and ViiV Healthcare and has received consultancy/advisory fees from Bristol-Myers Squibb, Gilead Sciences, Inc., Janssen Pharmaceuticals., Inc., Merck & Co., Inc., Abbvie, Inc., Teva, and ViiV Healthcare. P. E. S. has received research grants from Bristol-Myers Squibb, Gilead Sciences, Inc., and GlaxoSmithKline, and is a consultant or scientific advisory board member for Bristol-Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., GlaxoSmithKline, and Janssen Pharmaceuticals, Inc. K. M. is an employee and stockholder in Gilead Sciences, Inc. B. H. is an employee and stockholder of ViiV Healthcare. G. A. M. has served as a scientific advisor for Bristol-Myers Squibb, GlaxoSmithKline, Abbott, and Gilead Sciences, Inc.; has received payment for lectures from Bristol-Myers Squibb, GlaxoSmithKline, and Tibotec Therapeutics; has received research grants from Bristol-Myers Squibb, GlaxoSmithKline, Abbott, Merck & Co., Inc., and Gilead Sciences; and has served as the Data Safety Monitoring Board (DSMB) Chair for a Pfizer-sponsored study. Potential conflicts of interest."

"Financial support. This work was supported by Award Numbers U01AI068636, AI068634, AI38855 from the National Institute of Allergy and Infectious Diseases; UL1 RR 025005 from the National Center for Research Resources and the National Center for Advancing Translational Sciences; the National Institutes of Health supported by National Institute of Mental Health; and the National Institute of Dental and Craniofacial Research. Financial support."

"The ACTG A5224s was a metabolic substudy of A5202 (ClinicalTrials.gov NCT00118898) in which ART-naive study participants from ACTG sites in the United States and Puerto Rico aged ≥16 years and with an HIV-1 RNA level >1000 copies/mL were randomized to a blinded NRTI component, abacavir/lamivudine or tenofovir/emtricitabine, with either the open-label PI atazanavir/ritonavir or the non-NRTI (NNRTI) efavirenz. A secondary objective of A5224s was to compare the effects of initiating abacavir/lamivudine with those of tenofovir/emtricitabine on renal function after 96 weeks. A secondary renal objective was to compare the effects of atazanavir/ritonavir with efavirenz on these endpoints after 96 weeks. As previously described [], the NRTI assignment was prematurely unblinded for patients with A5202 screening HIV-1 RNA at least 100 000 copies/mL because of higher rates of virologic failure with abacavir/lamivudine regimens."